Opthea (OPT) Competitors

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Opthea.

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 0 mentions for Opthea. Aurinia Pharmaceuticals' average media sentiment score of 0.82 beat Opthea's score of -0.54 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Aurinia Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Aurinia Pharmaceuticals has a net margin of 101.46% compared to Opthea's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 27.47% beat Opthea's return on equity.

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 6.33%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Opthea.

Opthea has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -3.73%. Opthea's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Stoke Therapeutics currently has a consensus price target of $41.83, indicating a potential upside of 26.14%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Stoke Therapeutics is more favorable than Opthea.

Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Stoke Therapeutics has higher revenue and earnings than Opthea.

In the previous week, Stoke Therapeutics had 5 more articles in the media than Opthea. MarketBeat recorded 5 mentions for Stoke Therapeutics and 0 mentions for Opthea. Stoke Therapeutics' average media sentiment score of 0.83 beat Opthea's score of -0.54 indicating that Stoke Therapeutics is being referred to more favorably in the media.

56.0% of Opthea shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zymeworks has higher revenue and earnings than Opthea.

Zymeworks has a consensus target price of $37.89, indicating a potential upside of 38.39%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Opthea.

In the previous week, Zymeworks had 3 more articles in the media than Opthea. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Opthea. Zymeworks' average media sentiment score of 0.56 beat Opthea's score of -0.54 indicating that Zymeworks is being referred to more favorably in the news media.

Opthea has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Opthea has a net margin of 0.00% compared to Zymeworks' net margin of -76.56%. Opthea's return on equity of 0.00% beat Zymeworks' return on equity.

56.0% of Opthea shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Opthea has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -511.90%. Opthea's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Opthea has lower revenue, but higher earnings than Ocular Therapeutix.

Ocular Therapeutix has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 56.0% of Opthea shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 3.2% of Opthea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ocular Therapeutix had 15 more articles in the media than Opthea. MarketBeat recorded 15 mentions for Ocular Therapeutix and 0 mentions for Opthea. Ocular Therapeutix's average media sentiment score of -0.06 beat Opthea's score of -0.54 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Ocular Therapeutix presently has a consensus target price of $23.78, indicating a potential upside of 141.77%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Opthea.